Novavax, Inc.: A Leader in Biotechnology, Developing Next-Gen Vaccines to Combat Infectious Diseases Novavax, Inc. is a biotechnology company aiming to improve global health by discovering, developing, and commercializing vaccines that protect against serious infectious diseases. The company utilizes a unique vaccine platform that combines recombinant protein technology, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. With an eye towards tackling urgent public health crises, Novavax, Inc. is currently developing vaccines for COVID-19, influenza, and a potential dual vaccine for COVID-19 and influenza combined. The company's flagship product, NVX-CoV2373, is a COVID-19 vaccine, marketed under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted. It is designed for both adult and adolescent populations, as both a primary series and a booster for both homologous and heterologous indications. Beyond COVID-19, Novavax, Inc. is also prioritizing vaccine candidates for respiratory syncytial virus and malaria. Incorporated in 1987 and headquartered in Gaithersburg, Maryland, Novavax, Inc. is a leader in biotechnology, continuously working on innovative solutions to address pressing global health challenges.
Novavax's ticker is NVAX
The company's shares trade on the NASDAQ stock exchange
They are based in Gaithersburg, Maryland
There are 501-1000 employees working at Novavax
It is novavax.com/about-us
Novavax is in the Healthcare sector
Novavax is in the Biotechnology industry
The following five companies are Novavax's industry peers: